| __timestamp | Amicus Therapeutics, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 15746000 |
| Thursday, January 1, 2015 | 47269000 | 13392000 |
| Friday, January 1, 2016 | 71151000 | 9290000 |
| Sunday, January 1, 2017 | 88671000 | 7672000 |
| Monday, January 1, 2018 | 127200000 | 15293000 |
| Tuesday, January 1, 2019 | 169861000 | 22648000 |
| Wednesday, January 1, 2020 | 156407000 | 21864000 |
| Friday, January 1, 2021 | 192710000 | 37318000 |
| Saturday, January 1, 2022 | 213041000 | 48130000 |
| Sunday, January 1, 2023 | 275270000 | 108146000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Amicus Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc. have taken different paths in optimizing these costs.
From 2014 to 2023, Amicus Therapeutics has seen a staggering 1,230% increase in SG&A expenses, peaking at $275 million in 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Madrigal Pharmaceuticals has maintained a more conservative approach, with a 587% increase, reaching $108 million in the same year.
While Amicus's strategy suggests a focus on rapid growth, Madrigal's approach indicates a more measured expansion. Investors and stakeholders should consider these strategies when evaluating the long-term sustainability and profitability of these companies.
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.
Bausch Health Companies Inc. vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Arrowhead Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.